Last reviewed 2026-05-13 · How we verify

Cloderm (CLOCORTOLONE PIVALATE)

Cloderm (CLOCORTOLONE PIVALATE) is a corticosteroid medication developed by PROMIUS PHARMA LLC and currently owned by Legacy Pharma. It targets the glucocorticoid receptor and is used to treat various skin conditions, including atopic dermatitis, contact dermatitis, and plaque psoriasis. Cloderm is a small molecule corticosteroid that has been FDA-approved since 1977 and is now off-patent. It is available as a generic medication with a single manufacturer. Key safety considerations include the potential for skin thinning and other corticosteroid-related side effects.

At a glance

Approved indications

• Atopic dermatitis
• Contact dermatitis
• Discoid lupus erythematosus
• Eruption of skin
• Granuloma annulare
• Lichen simplex chronicus
• Plaque psoriasis
• Primary cutaneous T-cell lymphoma
• Pruritus ani
• Pruritus of genital organs
• Scalp psoriasis
• Seborrheic dermatitis

Common side effects

• Skin atrophy
• Miliaria
• Striae
• Secondary infection
• Maceration of the skin
• Allergic contact dermatitis
• Perioral dermatitis
• Hypopigmentation
• Acneiform eruptions
• Hypertrichosis
• Folliculitis
• Dryness

Key clinical trials

• Bio-equivalence Vasoconstriction Activity Study for Topically Applied Clocortolone Pivalate 0.1% Cream (PHASE1)
• Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Cloderm CI brief — competitive landscape report
• Cloderm updates RSS · CI watch RSS
• Legacy Pharma portfolio CI